These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12410086)

  • 1. Inclusion body myositis.
    Tawil R; Griggs RC
    Curr Opin Rheumatol; 2002 Nov; 14(6):653-7. PubMed ID: 12410086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inclusion body myositis--a review.
    Vogel H
    Adv Anat Pathol; 1998 May; 5(3):164-9. PubMed ID: 9868522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New insights in pathogenesis and therapy of sporadic inclusion body myositis (s-IBM)].
    Walter MC; Lochmüller H; Schlotter B; Reilich P; Müller-Felber W; Pongratz D
    Nervenarzt; 2001 Feb; 72(2):117-21. PubMed ID: 11256145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inclusion body myositis: old and new concepts.
    Amato AA; Barohn RJ
    J Neurol Neurosurg Psychiatry; 2009 Nov; 80(11):1186-93. PubMed ID: 19864656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging.
    Askanas V; Engel WK
    Scand J Rheumatol; 1998; 27(6):389-405. PubMed ID: 9855208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of inclusion body myositis.
    Cherin P
    Curr Opin Rheumatol; 1999 Nov; 11(6):456-61. PubMed ID: 10551668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features.
    Brady S; Squier W; Hilton-Jones D
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1240-6. PubMed ID: 23864699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease.
    Askanas V; Engel WK
    J Neuropathol Exp Neurol; 2001 Jan; 60(1):1-14. PubMed ID: 11202170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1β-induced accumulation of β-amyloid and cell death.
    Schmidt J; Barthel K; Zschüntzsch J; Muth IE; Swindle EJ; Hombach A; Sehmisch S; Wrede A; Lühder F; Gold R; Dalakas MC
    Brain; 2012 Apr; 135(Pt 4):1102-14. PubMed ID: 22436237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dermatomyositis with inclusion body myositis pathology.
    Layzer R; Lee HS; Iverson D; Margeta M
    Muscle Nerve; 2009 Sep; 40(3):469-71. PubMed ID: 19623629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the mitochondrial DNA abnormalities in the skeletal muscle of patients with inclusion body myositis.
    Horvath R; Fu K; Johns T; Genge A; Karpati G; Shoubridge EA
    J Neuropathol Exp Neurol; 1998 May; 57(5):396-403. PubMed ID: 9596410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sporadic Inclusion Body Myositis: An Acquired Mitochondrial Disease with Extras.
    De Paepe B
    Biomolecules; 2019 Jan; 9(1):. PubMed ID: 30621041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment.
    Schmidt K; Schmidt J
    Curr Opin Rheumatol; 2017 Nov; 29(6):632-638. PubMed ID: 28832349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoid-sensitive hereditary inclusion body myositis.
    Naumann M; Reichmann H; Goebel HH; Moll C; Toyka KV
    J Neurol; 1996 Feb; 243(2):126-30. PubMed ID: 8750548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inclusion body myositis: clinical and pathological boundaries.
    Amato AA; Gronseth GS; Jackson CE; Wolfe GI; Katz JS; Bryan WW; Barohn RJ
    Ann Neurol; 1996 Oct; 40(4):581-6. PubMed ID: 8871577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of inclusion body myositis with cyclosporin-A or tacrolimus: successful long-term management in patients with earlier active disease and concomitant autoimmune features.
    Quartuccio L; De Marchi G; Scott CA; Ferraccioli G; Beltrami CA; De Vita S
    Clin Exp Rheumatol; 2007; 25(2):246-51. PubMed ID: 17543149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple mitochondrial DNA deletions in hereditary inclusion body myopathy.
    Jansson M; Darin N; Kyllerman M; Martinsson T; Wahlström J; Oldfors A
    Acta Neuropathol; 2000 Jul; 100(1):23-8. PubMed ID: 10912916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory myopathy with cytochrome oxidase negative muscle fibers: methotrexate treatment.
    Levine TD; Pestronk A
    Muscle Nerve; 1998 Dec; 21(12):1724-8. PubMed ID: 9843075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermatomyositis with the features of inclusion body myositis associated with carcinoma of the bladder.
    Talanin NY; Bushore D; Rasberry R; Rudolph T; Tuli M; Friedman-Musicante R
    Br J Dermatol; 1999 Nov; 141(5):926-30. PubMed ID: 10583182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inclusion body myositis pathomechanism and therapy].
    Váncsa A; Dankó K
    Orv Hetil; 2008 Jul; 149(30):1413-8. PubMed ID: 18621600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.